Clinical Trial Update: A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing the effects of interleukin-2 (Proleukin) in HIV-positive patients with CD4 counts >300 cells/mm3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 3 | Status: COMPLETED